Anti-PD1 therapy achieved better outcomes in non-liver cancer patients with HBV infection

Wenfei Jin, Jie Zhou, Guanming Chen, Jiuling Wang, Bo Zhou, Xuemin Sun, Jinsong Wang, Shu Tang, Xiangju Xing, Xiaofei Hu, Yang Zhao, Peng Yu, Wenjiong Shi, Tingting Zhao, Yuzhang Wu, Ní Hóng, Zhihua Ruan, Yi ZhangResearch Square 2022 · DOI

Abstract

While anti-PD1 therapy has transformed the treatment landscape for various malignancies, the impact of chronic Hepatitis B virus (HBV) infection on treatment efficacy in non-liver cancers has remained poorly understood. This study investigated the clinical outcomes and immunological mechanisms underlying the response to anti-PD1 therapy in HBV-positive (HBV+) versus HBV-negative (HBV-) non-liver cancer patients. Through a multicenter retrospective analysis and single-cell RNA sequencing (scRNA-seq), the researchers demonstrate that HBV+ patients achieve significantly better clinical outcomes. This enhanced response appears to be driven by a higher baseline of "rechargeable" exhausted T cells and increased antigen presentation capacity in B cells following treatment.

Introduction

Immune checkpoint blockade (ICB), particularly anti-PD1 therapy, has become a cornerstone of modern oncology. However, patient response remains heterogeneous. Historically, patients with chronic HBV infection were often excluded from clinical trials for non-liver cancers due to concerns regarding viral reactivation or unpredictable immune-related adverse events (irAEs). Given the high global prevalence of HBV, understanding its influence on the immune microenvironment of non-liver malignancies is critical. This study explores the counterintuitive hypothesis that the chronic immune stimulation provided by HBV might actually prime the immune system for a more robust response to checkpoint inhibition.

Methods

The researchers conducted a multicenter retrospective study involving 84 non-liver cancer patients (35 HBV+, 49 HBV-) treated with anti-PD1 therapy between 2018 and 2022. To ensure comparability, patients were matched for cancer type, age, and gender.

To investigate the underlying cellular mechanisms, single-cell RNA sequencing (scRNA-seq) was performed on peripheral blood mononuclear cells (PBMCs) from three patients with esophageal squamous cell carcinoma (ESCC)—one HBV- and two HBV+—at pre- and post-treatment time points. A total of 44,253 individual immune cells were analyzed. The study also utilized a "Population Change Index" (PopIndex) to quantify shifts in immune cell subsets and validated findings using external datasets, including The Cancer Genome Atlas (TCGA) and previously published scRNA-seq data.

Results

Clinical Efficacy and Safety

The clinical analysis revealed a significant advantage for HBV+ patients. The Objective Response Rate (ORR) was 42.86% in the HBV+ group compared to 14.29% in the HBV- group. Statistical analysis showed that HBV+ patients had 4.41 times higher odds of responding to anti-PD1 therapy (95% CI: 1.43–14.99). Importantly, the therapy was found to be safe; there was no significant increase in irAEs in the HBV+ cohort compared to the HBV- cohort, suggesting that chronic HBV status does not preclude the safe use of ICB in non-liver cancers.

Mechanistic Insights: The Paradox of Exhaustion

Single-cell analysis provided a potential explanation for the superior outcomes in HBV+ patients. The researchers observed that HBV+ patients had a higher fraction of "Exhaustion-high" CD8+ T cells ($Exhaustion^{hi} T$) at baseline. While exhaustion is typically associated with reduced effector function, in the context of ICB, these cells represent a pool of highly suppressed but "rechargeable" lymphocytes. The transition from an exhausted state to a cytotoxic effector state was more pronounced in HBV+ responders following anti-PD1 therapy.

Multi-lineage Immune Response

The study also highlighted the role of B cells. Post-treatment, B cells in HBV+ patients exhibited a significant increase in MHC II expression, indicating enhanced antigen presentation capacity. This suggests that the benefits of anti-PD1 therapy in the context of HBV infection involve a coordinated response across multiple immune lineages, not just CD8+ T cells.

Identification of a Potential Biomarker

A specific subset of CD8+ effector T cells, characterized by high expression of $CX3CR1$ ($CX3CR1^{high} T_{EFF}$), was identified as a key player. This subset was significantly enriched in HBV+ responders. Conversely, $CX3CR1^{low}$ cells were associated with poorer prognosis in external TCGA datasets, suggesting that $CX3CR1$ expression could serve as a valuable biomarker for predicting ICB response.

Discussion

These findings suggest that the chronic immune pressure exerted by HBV infection induces a state of "primed" immunosuppression. This state, characterized by a high density of exhausted but reversible T cells, paradoxically makes the immune system more responsive to the reinvigorating effects of anti-PD1 therapy. This study challenges the traditional view of chronic viral infection as a purely negative factor in cancer immunotherapy and suggests that viral status should be considered in patient stratification.

Conclusion

Anti-PD1 therapy is both safe and more effective in HBV+ non-liver cancer patients compared to their HBV- counterparts. The enhanced efficacy is likely due to a more robust "recharging" of the immune system from a baseline of HBV-induced exhaustion. Future prospective trials are needed to validate these findings and further explore the potential of viral-induced immune signatures as predictive biomarkers in oncology.

Summary updated

Abstract

<title>Abstract</title> Anti-PD1 therapy has shown promising outcomes in different types of cancer. It is valuable to analyze whether the efficacy of anti-PD1 therapy has been impacted in cancer patients infected with hepatitis B virus (HBV) since the comorbidity of HBV and cancer cannot be neglected. We designed a multicenter retrospective study to evaluate the efficacy of anti-PD1 therapy on non-liver cancer patients infected with HBV. In addition, we performed single-cell RNA-seq (scRNA-seq) on peripheral blood mononuclear cells (PBMCs) from esophageal squamous cell carcinoma (ESCC) patients to compare the responses of HBV + ESCC patients and HBV- ESCC patients to anti-PD1 therapy. We found anti-PD1 therapy achieved better outcomes in HBV + non-liver cancer patients than their HBV- counterparts. Further analysis showed cytotoxicity of T cells and antigen presentation capacity of B cells significantly increased after anti-PD1 therapy in the 2 HBV + ESCC patients. We also identified CX3CR1<sup>high</sup> T<sub>EFF</sub>, a subset of CD8<sup>+</sup> T<sub>EFF</sub>, associated with better clinical outcome of HBV + patients. Lastly, we found CD8<sup>+</sup> T<sub>EFF</sub> from HBV + patients have higher fraction of Exhaustion<sup>hi</sup> T and lower cytotoxicity score than their HBV- counterpart. In summary, Anti-PD1 therapy on HBV + non-liver patients is safe and achieves better outcomes than that on HBV- non-liver patients, potentially because HBV + patients had stronger immunosuppression which made them more efficiently respond to anti-PD1 therapy.
BibTeX
@inproceedings{jin2022anti,
  author = {Wenfei Jin and Jie Zhou and Guanming Chen and Jiuling Wang and Bo Zhou and Xuemin Sun and Jinsong Wang and Shu Tang and Xiangju Xing and Xiaofei Hu and Yang Zhao and Peng Yu and Wenjiong Shi and Tingting Zhao and Yuzhang Wu and Ní Hóng and Zhihua Ruan and Yi Zhang},
  title = {{Anti-PD1 therapy achieved better outcomes in non-liver cancer patients with HBV infection}},
  booktitle = {Research Square},
  year = {2022},
  doi = {10.21203/rs.3.rs-1888416/v1},
}
Figure